Pfizer (PFE) says its Paxlovid forecast assumes that Covid infection rates will again decline in 2026 and “we expect this will be especially true in Q1,” given the current trends. Continues to expect “stable” revenue contributions from non-Covid products portfolio.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer sees declining Covid trends continuing into next year
- Pfizer in ‘strong position’ to help address substantial unmet needs in obesity
- Pfizer CEO says business ‘not as dependent’ on Covid anymore
- Pfizer Revises 2025 Revenue Guidance to $62 Billion
- Pfizer says ‘on track’ to deliver majority of $7.2B cost savings by 2026